Figure S2 from <i>De Novo</i> and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways

類似資料

• Figure S1 from <i>De Novo</i> and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways
  著者:: Subhamoy Chakraborty (16648124)
  出版事項: (2025)
• Figure S3 from <i>De Novo</i> and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways
  著者:: Subhamoy Chakraborty (16648124)
  出版事項: (2025)
• Supplementary Tables 1-3 from <i>De Novo</i> and Histologically Transformed Small-Cell Lung Cancer Is Sensitive to Lurbinectedin Treatment Through the Modulation of EMT and NOTCH Signaling Pathways
  著者:: Subhamoy Chakraborty (16648124)
  出版事項: (2025)
• Filamin A KO and S2152A KI reduce KSHV de novo infection of cell-free virions.
  著者:: Xiaojuan Li (351842)
  出版事項: (2025)
• Filamin A KO and S2152A KI reduce KSHV de novo infection and cell-contact mediated viral infection.
  著者:: Xiaojuan Li (351842)
  出版事項: (2025)